Surabhi Dangi-Garimella, PhD

A study presented by researchers from Massachusetts General Hospital (MGH), which queried the effect of thoracic radiotherapy and immune checkpoint inhibition on the risk of pneumonitis or immune-related adverse events (irAEs), found that radiotherapy did not increase patient risk for pneumonitis and that elevated expression of lactate dehydrogenase (LDH) could be a predictor of grade 2 or higher irAEs.

In a discussion on state-of-the-art uses for immunotherapy in the management of non—small cell lung cancer (NSCLC) at the American Society of Clinical Oncology Annual Meeting, oncologists shared their experiences with managing toxicities from immunotherapy and discussed the role of immunotherapy in specific patient populations.

An early stage international clinical trial is actively enrolling patients with relapsed, advanced or metastatic non—small cell lung cancer (NSCLC) to evaluate response to a combination of atezolizumab and daratumumab, according to a study at the 2017 Annual Meeting of the American Society of Clinical Oncology that detailed the trial design.

Managing heavily pretreated, often less fit, patients with relapsed/refractory multiple myeloma is a challenge in routine practice, as illustrated by the fact progression-free survival remains short, although daratumumab-based combination therapies are proven effective, according to results presented during a poster session at the 2017 American Society of Clinical Oncology Annual Meeting.

A phase 1 study, presented at the 2017 Annual Meeting of the American Society of Clinical Oncology, found that using daratumumab, an antibody that binds and inhibits the CD38 receptor, can improve patient response to treatment.

Updated trial results at the 2017 Annual Meeting of the American Society of Clinical Oncology showed the combinations of daratumumab with either lenalidomide and dexamethasone or bortezomib and dexamethasone prolonged progression-free survival for patients with relapsed refractory multiple myeloma.

The comittee voted 17-0 in favor of the Amgen/Allergan bevacizumab biosimilar candidate, ABP 215, and 16-0 in favor of Mylan’s trastuzumab biosimilar candidate, MYL-1401O.

CTL019 was unanimously approved by FDA’s Oncologic Drugs Advisory Committee (ODAC) for the treatment of children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia.

A new study, published by researchers at Massachusetts General Hospital, has questioned the traditional model of cancer metastases that implicates lymph nodes in helping seed cancer cells at distant sites.

Biosimilar molecules have gained access to the US market, and providers and patients are steadily warming up to the idea of using these products, but challenges still exist. Here are 5 of the recent developments in the biosimilar landscape.

A new liquid biopsy test that uses flow cytometry to detect cancer cells has been FDA approved for chronic leukemia, acute leukemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome, and myeloproliferative neoplasms.

The study, published in Lancet Oncology, has found that nivolumab reduced the rate of clinically meaningful deterioration compared with investigator’s choice among platinum-refractory patients being treated for recurrent or metastatic head and neck cancer.

On Monday, June 26, 2017, the Biden Foundation announced the launch of the Biden Cancer Initiative, their new venture to continue the fight to make progress in cancer prevention, detection, treatment, and care.

At the 8th Annual Oncology Market Access & Pricing USA 2017 meeting hosted by eyeforpharma, the discussion included raw material short supplies, pragmatic trials, risk-sharing, and understanding these challenges to meet stakeholder goals.

Researchers at Indiana University have confirmed the clinical utility of 2 laboratory tests that can distinguish benign pancreatic cancer lesions that mimic early signs of cancer and spare patients of unnecessary pancreatic cancer screenings or surgeries.

At the 8th Annual Oncology Market Access & Pricing USA 2017 meeting hosted by eyeforpharma, Sriram Shankar, senior consultant, INC Strategy Consulting, shared his thoughts on the implications of value frameworks for payer strategy.

According to a research study published in the journal Cancer, Asian women are less likely than non-Hispanic white women to receive timely follow-up after an abnormal screening mammogram.

A collaborative study among scientists working across 3 continents has found a strong association between circulating free DNA in patients being treated with olaparib (Lynparza) for prostate cancer and disease outcome.

At the 8th Annual Oncology Market Access & Pricing USA 2017 meeting hosted by eyeforpharma, pharmaceutical developers shared strategies on how a “value” culture can be infused right from the preclinical stage of oncology product development.

A meta-analysis spearheaded by The International Testicular Cancer Consortium has identified new susceptibility loci in the human genome that can increase a person’s risk of developing inherited testicular germ cell tumors.

An update on the latest developments in clinical and healthcare services research in oncology.

A rundown of sessions at The Community Oncology Alliance (COA) annual meeting, held April 27-28, 2017, near Washington DC. This year’s theme was Fueling the Cancer Moonshot.

A roundup of the panels and sessions at the National Comprehensive Cancer Network's 22nd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care, held March 23-25, 2017, Oralndo, Florida.

Data presented by the FDA at the 2017 American Society of Clinical Oncology Annual Meeting identified a need for educating community-based oncology practices on testing for programmed death-ligand 1 (PD-L1) protein expression before patients diagnosed with metastatic non-small cell lung cancer (mNSCLC) are treated with nivolumab or pembrolizumab.

The theme of this year's American Society of Clinical Oncology (ASCO) Annual Meeting was Making a Difference in Cancer Care With You.

A new study analyzing breast cancer data in the SEER database has concluded that small tumors detected following a mammography might be small because they are slow-growing, and not necessarily because they were detected early.

A discussion at the 2017 American Society of Clinical Oncology Annual Meeting addressed the practical solutions to address the financial toxicity of cancer care and identified leads for future intervention studies aiming to prevent or reduce this burden.

Updated results from the POLLUX and CASTOR trials, presented at the 2017 American Society of Clinical Oncology Annual Meeting, have found that including daratumumab in standard-of-care regimens prolonged progression-free survival (PFS) and improved the depth of response, independent of the patients’ cytogenetic risk.

At the 2017 American Society of Clinical Oncology Annual Meeting, oncologists heard from fellow experts on the best way to navigate this daunting payment reform challenge.

A phase 3, randomized, double-blind registration study in patients with breast cancer receiving neoadjuvant myelosuppressive chemotherapy has found clinical equivalence between filgrastim and its biosimilar after switching studies.